Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Accounts Payables (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Accounts Payables for 14 consecutive years, with $6.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables rose 47.63% year-over-year to $6.1 million, compared with a TTM value of $6.1 million through Sep 2025, up 47.63%, and an annual FY2024 reading of $5.5 million, up 114.39% over the prior year.
  • Accounts Payables was $6.1 million for Q3 2025 at Sunshine Biopharma, up from $4.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $6.1 million in Q3 2025 and bottomed at $42942.0 in Q4 2021.
  • Average Accounts Payables over 5 years is $2.5 million, with a median of $2.6 million recorded in 2023.
  • Peak annual rise in Accounts Payables hit 6426.94% in 2022, while the deepest fall reached 35.9% in 2022.
  • Year by year, Accounts Payables stood at $42942.0 in 2021, then skyrocketed by 6426.94% to $2.8 million in 2022, then fell by 7.75% to $2.6 million in 2023, then surged by 114.39% to $5.5 million in 2024, then increased by 10.72% to $6.1 million in 2025.
  • Business Quant data shows Accounts Payables for SBFM at $6.1 million in Q3 2025, $4.8 million in Q2 2025, and $5.0 million in Q1 2025.